~~<i id='1DC5919F22'><strike id='1DC5919F22'><tt id='1DC5919F22'><pre id='1DC5919F22'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

knowledge

author：focus 2025-10-01 22:48:39 - browse：6861

People taking notes while sitting around a meeting table — Adobe

It makes sense in theory for hospitals and startups to strike deals. Not only would doctors get first dibs on new health care technologies, their organizations would see windfalls if those startups hit it big.

In practice, it often doesn’t work out that way. Doctors and other clinicians have their own way of doing things, and they typically don’t take kindly to an administrator telling them to learn a new product, especially if the goal is financial gain.

Several health system-venture capital arrangements have fallen victim to this dynamic — but VC firm General Catalyst said this week it will buy nonprofit Summa Health, anyway.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Investment in vaccine development is lagging, report finds

entertainment

focus

leisure time

hotspot

knowledge

focus

AdobeAfterhissecondhospitalizationforacuteCovid-19,TonyMarksexpectedtogetbetter.Thenpaininvadedthe54

WSS

Protect nursing home residents from future pandemics

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Syphilis numbers in the United States reach record heights

Hospitals need to get ahead of regulations on climate change

Lawsuit challenges CMS nursing home minimum staffing rule

Wegovy leads to weight loss. Can it treat depression, too?

focus

knowledge

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

New research sheds light on how often breast cancer is overdiagnosed

Psychedelics group wrestles with new pharma identity

The Affordable Care Act has saved billions in health care costs

Guidelines to prevent youth baseball injuries need more muscle

New clues to why women have higher risk of autoimmune disorders

United colonoscopy coverage change 'may cost lives,' doctors say

Why Medicare shouldn’t cover every FDA

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

focus

Readout Newsletter: The latest on Novavax, Merck, Bluebird

The world needs the new pandemic treaty

Medicare drug price negotiation legal challenge met with skepticism

Philips to halt sales of sleep apnea machines in U.S.

Why we need mandatory labeling of GMO products

Boston competes with Raleigh

leisure time

hotspot

knowledge

focus